Pricing Log in Create free account
Friday 6 November 2026 Export UTHR’s income statement to Excel — free account

United Therapeutics Corporation

UTHR Healthcare Drug Manufacturers Specialty & Generic

United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.

Revenue
+4.13%
EPS
−21.7%
Free cash flow
−63.7%

Quarter to September 2026, against a year earlier

564.88 43.61 −7.17%
Market cap
$24.3B
P/E
19.7×
Fwd P/E
22.5×
Dividend yield
—
F-score
8/9
Altman Z
19.55
Beneish M
−2.26
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

United Therapeutics Corporation (UTHR) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, United Therapeutics Corporation (UTHR) trades at a EV/EBITDA of 14.7×. Over the past ten years it has ranged from 0.0× (March 2020) to 24.4× (April 2015); the current reading is higher than 88% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 12.2× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 12.0× 33.16%
FY2024 9.0× 33.88%
FY2023 6.7× (34.73%)
FY2022 10.3× (29.08%)
FY2021 14.6× 58.17%
FY2020 9.2× —
FY2019 0.0× —
FY2018 4.5× (38.60%)
FY2017 7.4× 53.86%
FY2016 4.8× (43.96%)

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 14.0× 1.22%
Jun 2026 13.9× (11.68%)
Mar 2026 15.7× 30.73%
Dec 2025 12.0× 19.16%
43 more quarters

Against its own ten years

Low 0.0× High 24.4×
Ten-year median 7.6×
Current reading's percentile 88

EV/EBITDA against peers

Company EV/EBITDA
ZTS Zoetis Inc. compare 10.7×
TAK Takeda Pharmaceutical Co. compare 11.2×
HLN Haleon PLC Sponsored ADR compare 12.2×
VTRS Viatris Inc. compare 12.3×
UTHR United Therapeutics Corporation 14.7×
NBIX Neurocrine Biosciences, Inc. compare 16.5×
ELAN Elanco Animal Health Incorporated compare 19.7×
RDY Dr. Reddy's Laboratories Ltd compare 22.9×
TEVA Teva Pharmaceutical Industries Ltd. compare 26.2×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on UTHR